JP7094231B2 - がんにおけるシグマ受容体リガンドの使用 - Google Patents

がんにおけるシグマ受容体リガンドの使用 Download PDF

Info

Publication number
JP7094231B2
JP7094231B2 JP2018564983A JP2018564983A JP7094231B2 JP 7094231 B2 JP7094231 B2 JP 7094231B2 JP 2018564983 A JP2018564983 A JP 2018564983A JP 2018564983 A JP2018564983 A JP 2018564983A JP 7094231 B2 JP7094231 B2 JP 7094231B2
Authority
JP
Japan
Prior art keywords
pyrazole
compound
pharmaceutical composition
yloxy
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018564983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517572A5 (enExample
JP2019517572A (ja
Inventor
ザマニーロ－カスタネード ダニエル
パラドス－サラザール ホセ－カルロス
ビデラ－セス セバスティア
ベラ エルナンデス ホセ－ミグエル
プラタ－サラマン カルロス－ラモン
ブルーナ－エスクエール ジョルディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Esteve Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals SA filed Critical Esteve Pharmaceuticals SA
Publication of JP2019517572A publication Critical patent/JP2019517572A/ja
Publication of JP2019517572A5 publication Critical patent/JP2019517572A5/ja
Application granted granted Critical
Publication of JP7094231B2 publication Critical patent/JP7094231B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018564983A 2016-06-06 2017-06-05 がんにおけるシグマ受容体リガンドの使用 Active JP7094231B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382258 2016-06-06
EP16382258.8 2016-06-06
PCT/EP2017/063614 WO2017211763A1 (en) 2016-06-06 2017-06-05 Use of sigma receptor ligands in cancer

Publications (3)

Publication Number Publication Date
JP2019517572A JP2019517572A (ja) 2019-06-24
JP2019517572A5 JP2019517572A5 (enExample) 2020-07-16
JP7094231B2 true JP7094231B2 (ja) 2022-07-01

Family

ID=56134287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018564983A Active JP7094231B2 (ja) 2016-06-06 2017-06-05 がんにおけるシグマ受容体リガンドの使用

Country Status (8)

Country Link
US (1) US20190142840A1 (enExample)
EP (1) EP3463339B1 (enExample)
JP (1) JP7094231B2 (enExample)
CN (1) CN109310672B (enExample)
AR (1) AR108682A1 (enExample)
ES (1) ES2969815T3 (enExample)
TW (1) TW201808300A (enExample)
WO (1) WO2017211763A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510767A (ja) 2004-08-27 2008-04-10 ラボラトリオス デル ドクトール エステベ エセ．ア． シグマ受容体阻害剤
WO2010128309A1 (en) 2009-05-08 2010-11-11 Modern Biosciences, Plc. Combination therapy comprising a taxane and a sigma receptor ligand sauch as rimcazole
JP2013501754A (ja) 2009-08-14 2013-01-17 ラボラトリオス・デル・ドクター・エステベ・ソシエテ・アノニム 化学療法によって誘発された疼痛を予防しまたは治療するためのσリガンド
JP2013529206A (ja) 2010-05-21 2013-07-18 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 化学療法または放射線療法によって誘発される嘔吐を予防および／または治療するためのシグマリガンド

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064315A1 (en) 2009-11-25 2011-06-03 Laboratorios Del Dr. Esteve, S.A. 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
SI2531177T1 (sl) 2010-02-04 2016-10-28 Laboratorios Del Dr. Esteve, S.A. 4-(2-((5-metil-1(2-naftalenil)-1h-pirazol-3-il)oksi)etil)morpholin hidroklorid polimorfi in solvati

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510767A (ja) 2004-08-27 2008-04-10 ラボラトリオス デル ドクトール エステベ エセ．ア． シグマ受容体阻害剤
WO2010128309A1 (en) 2009-05-08 2010-11-11 Modern Biosciences, Plc. Combination therapy comprising a taxane and a sigma receptor ligand sauch as rimcazole
JP2013501754A (ja) 2009-08-14 2013-01-17 ラボラトリオス・デル・ドクター・エステベ・ソシエテ・アノニム 化学療法によって誘発された疼痛を予防しまたは治療するためのσリガンド
JP2013529206A (ja) 2010-05-21 2013-07-18 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 化学療法または放射線療法によって誘発される嘔吐を予防および／または治療するためのシグマリガンド

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Biochemical and Biophysical Research Communications，2015年，Vol.456,No.2，p.683-688
Biochimica et Biophysica Acta，2015年，Vol.1848,No.10，p.2703-2714
Breast Cancer Research and Treatment，2004年，Vol.87,No.3，p.205-214
European Journal of Medicinal Chemistry，2014年，Vol.83，p.526-533
European Journal of Pharmacology，2011年，Vol.670,No.1，p.74-84

Also Published As

Publication number Publication date
EP3463339C0 (en) 2023-12-06
WO2017211763A1 (en) 2017-12-14
US20190142840A1 (en) 2019-05-16
ES2969815T3 (es) 2024-05-22
CN109310672A (zh) 2019-02-05
CN109310672B (zh) 2022-05-03
TW201808300A (zh) 2018-03-16
EP3463339A1 (en) 2019-04-10
JP2019517572A (ja) 2019-06-24
AR108682A1 (es) 2018-09-12
EP3463339B1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
JP6158180B2 (ja) 乳がんの処置
DK2694072T3 (en) COMBINATION OF ACT-INHIBITOR RELATIONSHIP AND ABIRATERON FOR USE IN THERAPEUTIC TREATMENTS
JP6066421B2 (ja) 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法
CN111285913B (zh) 用于肿瘤治疗的11-脱氧皮质醇的17α,21-二酯
WO2013124826A1 (en) Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors
TW202019409A (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或bcl-2抑制劑與chop聯合用藥的協同抗腫瘤作用
JP2018525358A (ja) アピリモドを用いる癌の処置方法
KR20170125951A (ko) 화학요법에 의해 유도되는 통증의 예방 또는 치료를 위한 시그마 리간드
TW201529071A (zh) 癌症治療組合療法
EP4338741A1 (en) Pharmaceutical composition and use of multi-kinase inhibitor
EP3007692A1 (en) Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
WO2020079184A2 (en) Urea derivatives for treating and/or preventing cancer
JP7094231B2 (ja) がんにおけるシグマ受容体リガンドの使用
WO2014002922A1 (ja) 抗癌剤の併用による癌治療方法
WO2014038894A1 (ko) 에틸(2-메틸-3{(E)-[(나프타[2,1-b]퓨란-2-일카보닐)하이드라조노]메틸}-1H-인돌-1-일)아세테이트, 이의 유사체를 유효성분으로 포함하는 암 예방 및 치료용 조성물
TW201343169A (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
WO2020142745A1 (en) Methods of treating graft versus host disease and neoplastic disease with amide compounds
JP2021501160A (ja) 血液がんおよび固形がんの処置のためのカルシウム放出活性化カルシウムチャネルモジュレーター
AU2015256266B2 (en) BH4 antagonists and methods related thereto
JP2025542187A (ja) 進行性固形腫瘍の治療方法
JP2015163592A (ja) 抗癌剤の併用による癌治療方法
WO2019230679A1 (ja) 抗腫瘍剤及び腫瘍治療方法
JP2015163591A (ja) 抗癌剤の併用による癌治療方法
JP2014034535A (ja) Ｈｓｐ９０阻害剤とｖｅｇｆｒチロシンキナーゼ且つｐｄｇｆチロシンキナーゼ阻害剤の組み合わせ
JP2014091711A (ja) Ｈｓｐ９０阻害剤と抗腫瘍性白金錯体との組み合わせ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220621

R150 Certificate of patent or registration of utility model

Ref document number: 7094231

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250